Patents by Inventor William Denny
William Denny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132477Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: ApplicationFiled: December 13, 2021Publication date: April 25, 2024Applicant: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Publication number: 20240124439Abstract: The invention relates to imidazopyridines of Formula (I) and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: ApplicationFiled: December 13, 2021Publication date: April 18, 2024Applicant: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Katherine Lin Lee, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Publication number: 20220008125Abstract: An ablation device including an ablation applicator having a first applicator end portion, a second applicator end portion, and an elongate portion, a first catheter having a first distal end portion and a first proximate end portion, the first distal end portion being coupled to the first applicator end portion, and a second catheter having a second distal end portion and a second proximate end portion, the second distal end portion being coupled to the second applicator end portion to supply an ablation medium to the ablation applicator, the ablation applicator forms an applicator shape having an applicator size in a plane perpendicular to a longitudinal axis of the first catheter, and the coupling between the first distal end portion and the first applicator end portion transfers a rotational force applied to the first proximate end portion to the ablation applicator and thereby cause the applicator size to change.Type: ApplicationFiled: November 22, 2019Publication date: January 13, 2022Inventors: Gerald FISCHER, Claudia NIKE NOWAK, William DENNY
-
Patent number: 10544215Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.Type: GrantFiled: June 14, 2016Date of Patent: January 28, 2020Assignee: Genentech, Inc.Inventors: John A. Flygare, Thomas H. Pillow, Brian Safina, Vishal Verma, BinQing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
-
Patent number: 10442836Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.Type: GrantFiled: June 16, 2014Date of Patent: October 15, 2019Assignee: Genentech, Inc.Inventors: John Flygare, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
-
Patent number: 10369355Abstract: An implantable neural tissue electrode assembly includes a cylindrical electrode lead with at least one electrode contact on the outer surface of the electrode lead. An active distal end fixation anchor is located at the distal end of the electrode lead and is adapted to fasten to adjacent tissue by rotation in a fastening direction. A passive rear fixation anchor is located on the outer surface of the electrode lead offset a longitudinal distance back from the distal end and has at least one curved blade with a blade tip directed away from rotation in the fastening direction. The rear fixation anchor is adapted to permanently fasten to adjacent tissue by rotation opposite to the fastening direction so that the blade tip cuts into the adjacent tissue, and the electrode assembly is adapted such that physiological induced strains are distributed along the electrode lead.Type: GrantFiled: August 23, 2017Date of Patent: August 6, 2019Assignee: MED-EL Elektromedizinische Geraete GmbHInventors: Birthe Rubehn, William Denny, Markus Oberparleiter, Werner Lindenthaler
-
Publication number: 20170348523Abstract: An implantable neural tissue electrode assembly includes a cylindrical electrode lead with at least one electrode contact on the outer surface of the electrode lead. An active distal end fixation anchor is located at the distal end of the electrode lead and is adapted to fasten to adjacent tissue by rotation in a fastening direction. A passive rear fixation anchor is located on the outer surface of the electrode lead offset a longitudinal distance back from the distal end and has at least one curved blade with a blade tip directed away from rotation in the fastening direction. The rear fixation anchor is adapted to permanently fasten to adjacent tissue by rotation opposite to the fastening direction so that the blade tip cuts into the adjacent tissue, and the electrode assembly is adapted such that physiological induced strains are distributed along the electrode lead.Type: ApplicationFiled: August 23, 2017Publication date: December 7, 2017Inventors: Birthe Rubehn, William Denny, Markus Oberparleiter, Werner Lindenthaler
-
Publication number: 20160354485Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.Type: ApplicationFiled: June 14, 2016Publication date: December 8, 2016Applicant: Genentech, Inc.Inventors: John A. Flygare, Thomas H. Pillow, Brian Safina, Vishal Verma, BinQing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
-
Publication number: 20150165063Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.Type: ApplicationFiled: June 16, 2014Publication date: June 18, 2015Inventors: John Flygare, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
-
Patent number: 8222254Abstract: The invention relates to novel 5-hydroxytryptamine (5-HT) receptor modulator compounds of formula (I); wherein A, B, R1-R5, T, W, X, Y, Z and m are defined herein, to pharmaceutical compositions comprising these compounds and to their use in the treatment of conditions associated with 5-HT action.Type: GrantFiled: August 6, 2008Date of Patent: July 17, 2012Assignee: Prosarix LimitedInventors: Jonathan Richard Heal, Joseph Michael Sheridan, William Dennys Ormrod Hamilton, Simon James Grimshaw, Sorin Vasile Filip
-
Publication number: 20110256092Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: ApplicationFiled: March 14, 2011Publication date: October 20, 2011Applicant: SUPERGEN, INC.Inventors: Pasit Phiasivongsa, Sanjeev G. Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati, Yong Xu, Krzysztof Swierczek
-
Patent number: 7939546Abstract: Quinoline derivatives, particularly 4-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine-2-carboxylic acid; 3-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine; N-(4-(piperidin-4-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide; and N-(4-(piperidin-3-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide, or a physiologically acceptable salt thereof, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: GrantFiled: April 10, 2009Date of Patent: May 10, 2011Assignee: SuperGen, Inc.Inventors: Pasit Phiasivongsa, Sanjeev G. Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati, Yong Xu, Krzysztof Swierczek
-
Publication number: 20110105436Abstract: Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.Type: ApplicationFiled: March 10, 2009Publication date: May 5, 2011Applicants: AUCKLAND UNISERVICES LIMITED, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Sandra Turcotte, Denise A. Chan, Patrick D. Sutphin, Amato J. Giaccia, Michael P. Hay, William A. Denny, Muriel Marie Bonnet
-
Publication number: 20100292179Abstract: We describe the functional cloning and the use of a non-fungal inositol phosphoryceraminde synthase (IPC synthase) in a screening assay for the identification of agents that target and antagonize the activity of IPC synthase.Type: ApplicationFiled: January 19, 2007Publication date: November 18, 2010Applicant: The University of DurhamInventors: Paul William Denny, Ralph Thomas Schwarz, Hosam Shams-Eldin
-
Publication number: 20100261732Abstract: The invention relates to novel 5-hydroxytryptamine (5-HT) receptor modulator compounds of formula (I); wherein A, B, R1-R5, T, W, X, Y, Z and m are defined herein, to pharmaceutical compositions comprising these compounds and to their use in the treatment of conditions associated with 5-HT action.Type: ApplicationFiled: August 6, 2008Publication date: October 14, 2010Inventors: Jonathan Richard Heal, Joseph Michael Sheridan, William Dennys Ormrod Hamilton, Simon James Grimshaw, Sorin Vasile Filip
-
Patent number: 7790746Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives of formula (I), are provided: Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT 1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: GrantFiled: December 18, 2007Date of Patent: September 7, 2010Assignee: SuperGen, Inc.Inventors: Pasit Phiasivongsa, Sanjeev G. Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati
-
Publication number: 20100129320Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: ApplicationFiled: September 9, 2009Publication date: May 27, 2010Applicant: SUPERGEN, INC.Inventors: Pasit Phiasivongsa, Sanjeev G. Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati
-
Publication number: 20090285772Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: ApplicationFiled: April 10, 2009Publication date: November 19, 2009Applicant: SuperGen, Inc.Inventors: Pasit Phiasivongsa, Sanjeev G. Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati, Yong Xu, Krzysztof Swierczek
-
Publication number: 20090099106Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: ApplicationFiled: December 18, 2007Publication date: April 16, 2009Applicant: SUPERGEN, INC.Inventors: Pasit Phiasivongsa, Sanjeev G. Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati
-
Publication number: 20080175814Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: ApplicationFiled: October 12, 2007Publication date: July 24, 2008Applicant: SUPERGEN, INC.Inventors: Pasit Phiasivongsa, Sanjeev Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati